{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-062766","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2026-05-15T21:00:31+00:00","discovered_at":"2026-05-15T21:02:00.546253+00:00","generated_at":"2026-05-15T21:03:54.524142+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BrainStorm Q1 net loss $2.1M; cash below $0.2M; NurOwn Phase 3 preparations ongoing","bullets":["Net loss $2.1M ($0.19 per share) vs $2.9M ($0.45) in Q1 2025; operating loss $2.0M.","Cash, equivalents, and restricted cash $0.2M at March 31, 2026, down from $0.3M at Dec 31, 2025.","R&D expense $0.8M (down from $1.3M); G&A expense $1.3M (down from $1.8M).","Planning Phase 3b ENDURANCE trial of NurOwn for ALS, targeting ~200 patients; BLA submission planned after Part A.","Raised $2M via two private placements in Feb 2026; stockholders' deficit $11M; accounts payable $7.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-062766","json":"https://secwatch.observer/filing/0001104659-26-062766.json","markdown":"https://secwatch.observer/filing/0001104659-26-062766.md","text":"https://secwatch.observer/filing/0001104659-26-062766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/0001104659-26-062766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/tm2614771d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:03:54.524142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d54bcd310f4e3da58683b4fb2e3a111a394b0b6","claim":"BRAINSTORM CELL THERAPEUTICS INC. reported the three months ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was approximately $2.1 million, EPS Net loss per share for the three months ended March 31, 2026 and 2025 was $(0.19) and $(0.45), respectively..","evidence_excerpt":"BrainStorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/0001104659-26-062766-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2026 was approximately $2.1 million"},{"label":"EPS","value":"Net loss per share for the three months ended March 31, 2026 and 2025 was $(0.19) and $(0.45), respectively."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}